Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
1. To compare the efficacy of tofacitinib, in doses of 2 mg BID, 5 mg BID, 10 mg BID versus placebo on the ASAS20 response rate at Week 12 in subjects with active AS that have had an inadequate response to previous treatment. 2. To estimate the placebo-corrected dose response for the ASAS20 at Week 12 in subjects with active AS that have had an inadequate responst to previous treatment. 3. To compare the safety of tofacitinib at all doses versus placebo in all study subjects.
Critère d'inclusion
- Ankylosing spondylitis (AS)